Vial label design and print may vary between batches. Product specifications remain unchanged.
At a glance
Strength
5mg + 5mg per vial
Form
Lyophilised powder
Purity
≥ 99% (HPLC)
CAS number
863288-34-0 / 170851-70-4
Molecular weight
3368.7 + 711.9 g/mol
Certificate of Analysis
Batch CP-10-07 · Prime Peptides UK
Research blends
CJC-1295 No DAC + Ipamorelin
Synthetic research peptide · 5mg + 5mg · CAS 863288-34-0 / 170851-70-4
£39.95 In stock · ready to shipper vial · £0.00 per mg
Choose strengthPrice per vial
CJC-1295 No DAC + Ipamorelin 5mg + 5mg is coming soon. It goes on sale as soon as its batch certificate is published - every vial we sell has a matching CoA.
Bank transferBitcoin Encrypted checkout · card details are never taken on this site
Multi-item discount. Add any 2 items for 4% off the whole order, 7% at 3, 10% at 4. Applied automatically at checkout.
Free
Free lab add-on. Bacteriostatic water is included with every peptide order at no extra cost.
Lab essentials tap to add to this order
RUOResearch Use Only. Not for human or veterinary use. By purchasing you confirm you are a qualified researcher and accept responsibility for safe, lawful handling.
Same-day dispatch
Orders before 3:00 PM leave the same working day, tracked, in plain packaging. Free UK delivery over £200.
Secure payment
Bank transfer or Bitcoin over an encrypted checkout. No card details are stored or handled on this site.
Batch tested
Every batch is HPLC and mass spectrometry tested, and its certificate is published before it ships.
CJC-1295 No DAC + Ipamorelin 5mg + 5mg≥99% HPLC · In stock
£39.95
Compound Overview
What Is CJC-1295 (No DAC) + Ipamorelin 5mg + 5mg?
CJC-1295 (no DAC) + Ipamorelin 5mg + 5mg is a research peptide combination of two peptides studied for growth hormone signalling pathways that is combined in equal amounts. The resulting combination delivers 5mg of CJC-1295 (no DAC) along with 5mg of Ipamorelin for labs to use in a single research product. It is designed only for scientific and analytical research purposes and is not intended for use for human consumption or therapeutic purposes.
This research mixture is a blend of two synthetic peptides, which are linked to different parts of growth-hormone related signalling.
CJC-1295 (no DAC) is a type of synthetic growth hormone-releasing hormone (GHRH) analogue. This research type is referred to as “no DAC” because it differs from the CJC-1295 family where a Drug Affinity Complex (DAC) has been designed to affect the persistence of such compounds in biological systems. CJC-1295 (without DAC) is identified as a defined compound in scientific databases separately.
Ipamorelin (G3P) is a synthetic pentapeptide and ghrelin-receptor agonist, which has been studied as a growth hormone secretagogue. Early experimental research characterised it as having selective GH-releasing activity.
In this product, the quantity of each component is provided at 5mg, not 10mg (which refers to a single peptide). This is important for laboratory identification, inventory and experimental planning.
The combination is supplied strictly as research material and should not be interpreted as an approved medical preparation.
Sizes & Prices
CJC-1295 No DAC + Ipamorelin sizes and prices
Each size is supplied from its own tested batch with its own Certificate of Analysis. The size is the amount of research material in the vial; larger vials cost less per mg.
Size
Price
Per mg
Batch certificate
Choose
5mg + 5mg
£39.95
–
CP-10-07
10mg + 10mg
£69.95
–
CP-20-07
Technical Data
CJC-1295 No DAC + Ipamorelin Product Specifications
Technical Specification Sheet
CJC-1295 NO DAC + IPAMORELIN · RUO
Product
CJC-1295 (No DAC) + Ipamorelin
CJC-1295 quantity
5mg
Ipamorelin quantity
5mg
Total peptide material
10mg
Product type
Combined synthetic peptide research material
Research classification
GHRH analogue + growth hormone secretagogue
Testing documentation
Batch-specific analytical documentation/COA
Intended use
Laboratory and scientific research only
Market
United Kingdom
Human use
Not intended for human consumption or administration
CAS Number
863288-34-0 / 170851-70-4
Amino-Acid Sequence
Mod GRF 1-29 (29-mer) + Ipamorelin (pentapeptide)
Molecular Formula
C152H252N44O42 + C38H49N9O5
Molecular Weight
3368.7 + 711.9 g/mol
Purity
≥99% by HPLC
Researchers should consult the documentation supplied with the individual batch for analytical results, handling conditions and confirmed product specifications rather than assuming that specifications from another batch are interchangeable.
The Science
Scientific Background of the Two Peptides
CJC-1295-related compounds have been developed and investigated as synthetic analogues of growth hormone-releasing hormone. Published clinical research on the long-acting DAC-containing form of CJC-1295 demonstrated effects on GH and IGF-I secretion, but these findings should not automatically be transferred to CJC-1295 without DAC because the molecular formats have important pharmacological differences.
This distinction is particularly relevant when interpreting literature for a CJC-1295 no DAC research product. Researchers should confirm which molecular form was used in a study before treating its findings as directly applicable.
Ipamorelin has a separate experimental history. It is a synthetic pentapeptide described as a growth hormone secretagogue and ghrelin-receptor agonist. Preclinical work has investigated its receptor activity, GH-release characteristics and effects in several experimental models.
A combined CJC-1295 (no DAC) and Ipamorelin research format therefore brings together compounds associated with two distinct signalling approaches. That scientific rationale makes the combination relevant to mechanistic investigation, but it does not establish therapeutic efficacy or safety in humans.
Laboratory Focus
Why Are CJC-1295 and Ipamorelin Studied?
These peptides are the subject of a great deal of research, with the primary focus being on signalling related to the secretion of growth hormone, as well as on the experimental measurement of growth hormone secretion.
Growth Hormone Axis
Growth hormone analogues act on pathways involved in the physiological control of GH secretion, and growth hormone secretagogues like Ipamorelin have been investigated via the growth hormone secretagogue receptor. In initial studies, ipamorelin was found to have more selective GH-releasing activity than some of its predecessors.
Receptor Signalling
Laboratory studies could thus focus on topics like receptor signalling, responses of the endocrine pathways, peptide/receptor interactions, changes in biomarkers, analytical detection, and comparative peptide pharmacology.
Preclinical Models
Ipamorelin research has also been conducted in animal models beyond endocrine signalling such as gastrointestinal models. These studies are always context-specific and must not be used to suggest that the peptide is able to cure matching conditions in humans.
Metabolic Research
Analytical identification and detection is one of the other important research areas in CJC related peptides. The metabolism and detection of synthetic GHRH analogues, such as CJC-1295-related analogues, have been investigated. The evidence base is highly inconsistent for different compounds and molecular forms and, as such, it is important to make precise identification when considering scientific literature.
Product Format
Understanding the 5mg + 5mg Research Format
5mg + 5mg
Nominal Research Quantity
The 5mg + 5mg designation identifies the amount of each peptide supplied in the product: 5mg of CJC-1295 without DAC together with 5mg of Ipamorelin.
It should not be viewed as a recommended dosage, dosage amount or therapeutic regimen.
When it comes to a lab, it's better to use specific components rather than just ‘10mg'. It is important to understand that a 10mg total blend with equal parts of two peptides is not the same as a research product with 10mg of one peptide.
Material requirements will differ from laboratory to laboratory, depending on experimental design, number of analytical runs, procedures employed for the assays, controls, replications, scale of the study and the method used. Because of these differences, it's possible to discover different amounts of research peptides available.
Laboratory materials should be chosen based on protocols for which they have been validated and based on the requirements of the researcher's institution, and not on information about human or veterinary use.
This strength-specific identification also supports clearer stock management, documentation and batch traceability.
Verification
Quality Testing, Identification and Certificate of Analysis
Analytical documentation is particularly important with a two-component peptide product because researchers need confidence that the material corresponds to the compounds stated on the label.
Batch-Specific CoA
A Certificate of Analysis (COA) should be reviewed alongside the product and batch number. Depending on the analytical programme used by the supplier, documentation may include information relating to peptide identity, chromatographic analysis, reported purity and other batch-specific measurements.
HPLC Analysis
High-performance liquid chromatography (HPLC) is commonly used in peptide analysis to assess chromatographic purity, while other analytical techniques can contribute additional information about compound identity or composition.
Identity vs Purity
Researchers should not consider a purity figure as the sole indicator of product quality. Identification, traceability, appropriate analytical methodology, batch matching and transparent documentation all contribute to meaningful quality assessment.
The COA supplied for one batch should not automatically be assumed to represent another. Where batch-specific documentation is provided, researchers should verify that its identifying information corresponds with the material received.
Handling
Laboratory Storage and Handling Considerations
Contamination Control
Peptide research materials must be treated in laboratory conditions that ensure the integrity of the sample and avoid unnecessary degradation and contamination.
Environmental Conditions
Original product packaging, batch label and accompanying documentation to be kept to ensure the material is traceable throughout the research process. Some peptide materials can be adversely impacted by inappropriate temperature conditions, excess light, moisture, or frequent changes of environment.
Documentation First
Specific storage requirements may be different depending on product form and supplied documentation. Laboratories should, therefore, follow the storage instructions supplied with the relevant batch and act in accordance with their established SOPs.
Reconstitution Practice
In cases where samples are being prepared for analytical or experimental purposes, it is also important to avoid contamination and to use clean laboratory techniques. These are only considerations for scientific handling and do not constitute instructions for preparation for human administration.
Researchers evaluating CJC-1295 (no DAC) + Ipamorelin 5mg + 5mg in the UK products should consider more than the amount shown on the label.
Clear identification of both compounds, a clear breakdown of the 5 mg + 5 mg composition, batch numbering, analytical documentation, storage information and supplier transparency can all help laboratories assess research materials before procurement.
A batch-specific Certificate of Analysis is particularly useful because it allows analytical information to be linked with the supplied material rather than relying solely on generic product claims.
UK researchers should also distinguish between research-only compounds and authorised medicines. MHRA guidance explains that unlicensed medicinal products do not hold UK marketing authorisation and may not have undergone MHRA assessment. Research products should therefore never be presented as authorised medicines simply because scientific literature exists concerning their constituent compounds.
Analytical Records
Batch certificates for CJC-1295 No DAC + Ipamorelin
Every order ships with the CoA matched to its batch number, and the analytical records
are published here - open the certificate before you order, or cross-check the one in
your parcel.
CJC-1295 No DAC + Ipamorelin — Frequently Asked Questions
What do CJC-1295 (no DAC) + Ipamorelin 5mg + 5mg mean?
It means the research product contains 5mg of CJC-1295 without DAC and 5mg of Ipamorelin, for 10mg of combined peptide material. The two quantities identify the material supplied for laboratory work; they do not represent a human dose or administration recommendation.
Is 5mg + 5mg the same as a single 10mg peptide?
No. The total nominal quantity is 10mg. But the actual product is two different substances at 5mg each. Researchers should record and analyze the product by its individual component quantities, not as 10mg of CJC-1295 or 10mg of Ipamorelin.
Why combine CJC-1295 without DAC and Ipamorelin for research?
The compounds are associated with different mechanisms within growth-hormone-related signalling. CJC-related peptides have been investigated as GHRH analogues, whereas Ipamorelin is a growth hormone secretagogue acting at the ghrelin/GHS receptor. Combining them can therefore be relevant to research examining interacting signalling pathways. This research rationale does not demonstrate clinical benefit.
Is CJC-1295 (no DAC) + Ipamorelin approved for human use in the UK?
This product is supplied as a Research Use Only laboratory material and is not presented as a UK-authorised medicine. Researchers should not interpret product availability or published experimental literature as evidence of MHRA approval for therapeutic use.
What should be checked on the Certificate of Analysis?
Researchers should confirm that the COA corresponds with the correct product and batch number. Relevant information may include compound identification, analytical method, reported test results and batch-specific data. The analytical documentation should be considered together with product labelling and traceability information.
Does research on CJC-1295 apply directly to the no-DAC version?
Not necessarily. Several studies of the long-acting DAC-containing analogue of CJC-1295 have been cited. Any researchers using CJC-1295 without DAC should ensure that the molecular form of CJC-1295 is the same as that used in the publications they are referring to in their experimental interpretations.
PG
Medically & Scientifically Reviewed By
Dr. Priyanka Goel
Scientific & Medical Content Reviewer
Reviews research content against current published literature and UK regulatory guidance, ensuring compound information is accurate, referenced and presented for research use only.
CJC-1295 (no DAC) + Ipamorelin 5mg + 5mg is intended for laboratory, analytical and scientific research only. It is not used for human or animal consumption, self-administration, diagnostic, therapeutic or veterinary purposes. No information contained herein should be considered medical advice or a recommendation for clinical use. Read results of published studies in relation to the molecular form, the model and the limitations of the specific study.
